Company: BUDZ
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001096906-25-000820
Chunk: 62

Company: WEED, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 62
---
 LLC, a Wyoming limited liability company, under which we acquired all of the issued and outstanding limited liability company membership units of Sangre in exchange for Five Hundred Thousand (500,000) shares of our common stock, restricted in accordance with Rule 144. As a result of this agreement, Sangre is a wholly-owned subsidiary of WEED, Inc.

This discussion and analysis should be read in conjunction with our financial statements included as part of this Quarterly Report.

 22Table of Contents

Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024

Results of Operations

  Three Months Ended   March 31,   2025  2024 Revenue $-  $-          Operating expenses:                 General and administrative  383,268   136,565 Professional fees  45,847   25,203 Depreciation and amortization  5,622   5,721 Total operating expenses  (434,737 )  (167,489)         Net operating loss  (434,737)  (167,489)         Other income (expense)        Interest expense  (5,718)  (3,163 )Total other income (expense) $(5,718) $(3,163)         Net Loss $(440,455 ) $(170,652 )         Other Comprehensive Income   75   17          Comprehensive Loss $(440,380 ) $(170,635 )

Operating Loss; Net Loss

Our comprehensive net loss increased by $269,745, from $(170,635) to $(440,380), from the three months ended March 31, 2024, compared to the three months ended March 31, 2025. Our net operating loss increased by $267,248 from $(170,053) to $(437,301) for the same period. The increase in our comprehensive net loss and operating loss is primarily a result of increases in general and administrative expenses and professional fees. These changes are detailed below.

Revenue 

We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we plan to be a company focused on purchasing